角膜缘干细胞移植结局的荟萃分析
结果显示自体移植(AULT和cAULT)在眼表改善率和视力提高率上均优于同种异体移植(ALLT和cALLT),且同种异体移植的复发上皮糜烂和眼压升高发生率更高。
要点
- 自体角膜缘干细胞移植的眼表改善率(AULT 85.7%,cAULT 84.7%)高于同种异体移植(ALLT 57.8%,cALLT 63.2%)。
- 自体移植的视力提高率(76%)显著优于其他三种术式(cAULT 56.4%,ALLT 52.3%,cALLT 43.3%,均P<.001)。
- ALLT的复发上皮糜烂率(27.8%)和眼压升高率(6.3%)最高,总体严重并发症发生率低。
核心结论
- 角膜缘干细胞移植可改善或稳定角膜表面,严重眼部并发症发生率低。
- 自体角膜缘干细胞移植可能比同种异体移植成功率更高且并发症更少。
研究设计与样本
- 系统检索PubMed、EMBASE、Web of Science和Cochrane数据库,无语言限制,最新检索至2019年6月30日。
- 纳入至少20眼且报告LSCT结局的临床研究,排除动物研究和其他手术干预研究。
主要发现
- AULT、ALLT、cAULT和cALLT的眼数分别为505、742、771和184。
- 总体眼表改善率为74.5%,AULT为85.7%(95%CI 79.5%-90.3%),cAULT为84.7%(95%CI 77.2%-90.0%),ALLT为57.8%(95%CI 49.0%-66.1%),cALLT为63.2%(95%CI 49.3%-75.2%)。
- 视力改善率:自体角膜缘移植为76%,cAULT为56.4%,ALLT为52.3%,cALLT为43.3%(均P<.001)。
- 所有受眼最常见不良事件为复发/持续性上皮糜烂(10.5%;95%CI 7.2%-23.3%)和眼压升高(1.7%;95%CI 0.5%-7.8%)。
- ALLT的复发上皮糜烂率最高(27.8%;95%CI 17.1%-41.9%),眼压升高率也最高(6.3%;95%CI 1.8%-19.4%)。
关键数值与推荐
- 纳入标准:临床研究且LSCT术后结局至少20眼;排除动物研究和其他手术干预研究。
- 异质性用I2统计量评估,荟萃分析采用随机效应模型。
临床怎么用
- LSCT可改善或稳定角膜表面,严重并发症发生率低。
- 自体角膜缘干细胞移植在眼表改善和视力提高方面可能优于同种异体移植,且并发症更少。
- 同种异体移植需关注复发上皮糜烂和眼压升高的风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Limbal stem cell transplant (LSCT) can be categorized as direct autologous limbal transplant (AULT), direct allogenic limbal transplant (ALLT), cultivated autologous limbal stem cells transplant (cAULT), and cultivated allogenic limbal stem cells transplant (cALLT). To our knowledge, there is no study directly comparing the outcomes and complications of these procedures. OBJECTIVE: To evaluate the outcomes of different LSCT procedures. DATA SOURCE: We searched PubMed, EMBASE, Web of Science, and Cochrane without language filter for peer-reviewed articles about LSCT. The latest search was performed on June 30, 2019. STUDY SELECTION: Clinical studies with the outcome of at least 20 eyes after LSCT were included. Animal studies and studies of other surgical interventions were excluded. DATA EXTRACTION AND SYNTHESIS: Two reviewers independently abstracted the data from each study. Heterogeneity was evaluated with the I2 statistic, and a meta-analysis was performed using the random-effects model. MAIN OUTCOMES AND MEASURES: Outcome measures included the improvement of ocular surface, visual acuity (VA), and adverse events of recipient eyes and donor eyes. RESULTS: Forty studies (2202 eyes) with a mean (SD) follow-up of 31.3 (20.9) months met the inclusion criteria. The mean (SD) age of study participants was 38.4 (13.1) years, and men accounted for 74%. The number of eyes that underwent AULT, ALLT, cAULT, and cALLT were 505, 742, 771, and 184, respectively. Improvement of the ocular surface was achieved in 74.5% of all eyes, 85.7% of eyes after AULT (95% CI, 79.5%-90.3%), 84.7% after cAULT (95% CI, 77.2%-90.0%), 57.8% after ALLT (95% CI, 49.0%-66.1%), and 63.2% after cALLT (95% CI, 49.3%-75.2%). Autologous limbal transplantation resulted in a greater VA improvement rate (76%) than did the other 3 procedures (cAULT: 56.4%; ALLT: 52.3%; cALLT: 43.3%; all P < .001). The most common adverse events in all recipient eyes were recurrent/persistent epithelial erosion (10.5%; 95% CI, 7.2%-23.3%) and elevated intraocular pressure (intraocular pressure, 1.7%; 95% CI, 0.5%-7.8%). Patients who underwent ALLT had the highest rate of recurrent epithelial erosion (27.8%; 95% CI, 17.1%-41.9%) and intraocular pressure elevation (6.3%; 95% CI, 1.8%-19.4%). CONCLUSIONS AND RELEVANCE: These findings suggest LSCT can improve or stabilize the corneal surface with a low rate of severe ocular complications and that autologous LSCT may have a higher success rate and fewer complications than allogenic LSCT.
引用
- Le Q, Chauhan T, Yung M, et al. Outcomes of Limbal Stem Cell Transplant: A Meta-analysis. JAMA Ophthalmol. 2020. PMID: 32324211. doi:10.1001/jamaophthalmol.2020.1120
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。